AimTo assess the association of GLO1 C332C gene polymorphism with breast cancer risk at different stages of the disease and to investigate the effect of this gene polymorphism on its mRNA expression and enzyme activity.MethodsGLO1 C332C gene polymorphism was analyzed by PCR-RFLP in 100 healthy controls and 200 patients with breast cancer (100 patients with stage I & II and 100 patients with stage III & IV). GLO1 mRNA expression was measured by real time PCR. Serum GLO1 enzyme activity was measured colorimetrically.ResultsGLO1 A allele was associated with increased risk of breast cancer [OR (95%CI)= 2.8(1.9-4.1), P < 0.001]. Its frequency was significantly higher among advanced stages of breast cancer compared with localized tumors (OR (95%CI)= 1.9(1.3-2.9), p < 0.001). GLO1 mRNA expression and enzyme activity were significantly higher in breast cancer patients compared to controls and they were much higher in the advanced stages of the disease (P < 0.001). Carriers of AA genotype showed higher GLO1 expression and enzyme activity compared with carriers of CC genotype.ConclusionGLO1 C332C SNP was associated with overexpression of GLO1 mRNA and higher enzyme activity in breast cancer patients suggesting its role in the development of breast cancer and its progression from localized to advanced.

No abstract

Background: Long non-coding RNA ADAM metallopeptidase with thrombospondin type 1 motif, 9 antisense RNA 2 (ADAMTS9-AS2) was recognized as a novel tumor suppressor and plays an important role in the initiation and progression of malignant behavior in human cancers, although its plasma expression and clinical value in patients with non-small cell lung cancer (NSCLC) remain unknown. We aimed to analyze the diagnostic role of ADAMTS9-AS2 and cytokeratin 19 fragmentation antigen (CYFRA 21-1) in NSCLC.Methods: The present study included 80 control subjects, 80 patients with benign lung lesion and 80 NSCLC patients. The expression of ADAMTS9-AS2 in the tissue and plasma was detected by a real-time polymerase chain reaction. Serum CYFRA 21-1 was analyzed using an enzyme-linked immunosorbent assay.Results: In comparison with benign lung lesion and controls, tissue and plasma ADAMTS9-AS2 expression were significantly down-regulated in NSCLC (p < 0.001). Decreased ADAMTS9-AS2 expression was associated with TNM stages in NSCLC patients (p < 0.001). Up-regulation of CYFRA 21-1 was reported among NSCLC patients and it was associated with TNM staging. Tissue and plasma ADAMTS9-AS2 expression levels were the predicting factors for NSCLC and they both correlated negatively with CYFRA 21-1 levels. Plasma ADAMTS9-AS2 levels had a significant positive correlation with their tumor tissue levels. Plasma ADAMTS9-AS2 showed a higher sensitivity (95%) and specificity (99.1%) in the diagnosis of NSCLC than CYFRA 21-1 (61.3% sensitivity and 60% specificity).Conclusions: Our results suggested that decreased plasma ADAMTS9-AS2 expression might act as a novel non-invasive tumor biomarker in NSCLC diagnosis.

Background: Chemotherapy plays a significant part in the management of breast cancer. In the current study, mastectomy with prompt breast reconstruction, the effects of neoadjuvant and adjuvant chemotherapy were investigated. Objective: The effect of neoadjuvant and adjuvant were given systemically to breast cancer patients to investigate their effect on breast reconstruction following mastectomy. Methods: Two-year postoperative follow-up at Zagazig University Surgical Department for 82 patients who received assistance systemic neoadjuvant (NAC) and (ACT) adjuvant chemotherapy for breast cancer between January 2021 and December 2022, together with mastectomy and rapid reconstructive surgery of the breast. Results: During the trial, 82 patients received fast breast remodeling after mastectomy. 34 patients did not receive any systemic therapy, whereas 28 patients had preoperative chemotherapy and 20 patients received postoperative chemotherapy. Conclusion: There were no differences in unscheduled reoperation, donor-site complications, or expander loss across the groups although the adjuvant chemotherapy group had a substantial number of wounds that were infected.

Background: Both benign and malignant diseases now have more and more justifications for laparoscopic splenectomy, which is currently considered a standard technique for handling practically all disorders necessitating splenectomy. Objective: We aimed to contrast the consequences of benign versus malignant hematological diseases following laparoscopic splenectomy. Patients and Methods: We carried out seventy-six laparoscopic splenectomies between 2019 and 2022. 38 patients were handled with the use of a unique method, an anterior approach, but 38 patients have been positioned in a semi-lateral position for laparoscopic intervention. Result: Malignant disorder patients had older ages (60.1), whereas benign disorder sufferers had younger ages (35.6), P = 0.001. Laparoscopy was used in 72 of 76 cases (94.7%). Four situations (5.2%) have been modified to open cases. Operative time used to be 2.51 h/min for malignant in distinction to 2.30 h/min for benign tumors (P > 0.05). Conclusions: laparoscopic splenectomy is logically appropriate as a less invasive technique for benign splenomegaly, hematological tumors, or both.